EXPAREL™ - About EXPAREL™

EXPAREL^™ is designed to extend the duration of analgesia provided by the commonly used local analgesic, bupivacaine. By prolonging the effective dose of bupivacaine from 6 - 8 hours to several days, EXPAREL is expected to provide pain relief for the first few days following surgery when pain is most debilitating.

EXPAREL should also reduce the severity of adverse outcomes related to postoperative pain. Potential clinical and ultimately, economic benefits include:

A single perioperative administration minimizing further intervention from nurses, anesthetists, or surgeons for the treatment of pain.
Opioid sparing, which means the potential for less narcotic side effects.
Eliminating infusion pumps, catheters, etc., which can fail or complicate patient movement.
Potential for earlier mobility, and therefore faster, easier rehabilitation.
Earlier discharge from the hospital.
Unmet need: non-opioid therapy for postoperative pain.
EXPAREL designed for 72 hours of relief.

Estimated United States (US) and European surgical procedures
80 million

Estimated US surgical procedures
45 million
7.2 million uses of bupivacaine

Bupivacaine: most commonly used local anesthetic
"Gold standard" but 6 - 8 hours of relief

Unmet need: non-opioid therapy for the prevention and management of postop pain
EXPAREL designed for 72 hours of relief